金币
UID400479
帖子
主题
积分1746
注册时间2018-11-13
最后登录1970-1-1
听众
性别保密
|
发表于 2023-9-8 10:13:55
|
显示全部楼层
GAMP5 M3附录
5.3.1.2 System Impact
The initial risk assessment should determine the overall impact that the computerized system may have on patient safety, product quality, and data integrity due to its role within the business processes. This should take into account both the complexity of the process, and the complexity, novelty, and use of the system. Categorization assists in assessing system complexity and novelty (see Appendix M4).
In general, high impact systems typically include those that:- generate, manipulate, or control data supporting regulatory safety and efficacy submissions
- control critical parameters or data used at any stage, including pre-clinical, clinical, development, and manufacture
- control or provide data for product release
- control data required in case of product recall
- control adverse event or complaint recording or reporting
- support pharmacovigilance
Process knowledge assists with determining system impact (see Section 7.2 of this appendix for an example).
Systems that are of lower overall impact can be documented and tested less rigorously (see Section 5.7 of this appendix).
|
|